Company news
Kezar Life Sciences, Inc. news in 2020
Kezar Life Sciences, Inc.'s news releases, calls and decks from 2020, newest first.
Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences
November 11, 2020
Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates
November 4, 2020
Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis
October 22, 2020
Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
August 4, 2020
Kezar Announces Proposed Public Offering of Common Stock
June 7, 2020
Kezar Announces Pricing of a Public Offering of $46.7 million of Common Stock and Pre-Funded Warrants
June 7, 2020
Kezar Provides Data Update from MISSION Study of KZR-616
June 2, 2020
Kezar Announces Presentations During Upcoming Scientific Conferences
May 19, 2020
Kezar Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
May 6, 2020
Kezar Life Sciences Strengthens Executive Team with the Appointment of Noreen R. Henig, MD as Chief Medical Officer
May 3, 2020
Kezar Provides Statement Regarding COVID-19 Pandemic
April 8, 2020
Kezar Life Sciences Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update
March 11, 2020
Kezar Announces Closing of $56.8 Million Public Offering of Common Stock and Pre-Funded Warrants
February 3, 2020
Kezar Announces Pricing of $49.4 Million Public Offering of Common Stock and Pre-Funded Warrants
January 30, 2020
Kezar Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 29, 2020